| PESUB16 | The burden of and risk factors for maternal mental health and the impact on parenting by mothers living with HIV in rural Zimbabwe | Poster exhibition | Mental health (including depression and psychiatric manifestations) and HIV |
| PESUB17 | DTG associated weight gain: real or perceived? Real world experiences from Zimbabwe | Poster exhibition | Weight gain |
| PESUB18 | PROGRESSION OF HEPATIC STEATOSIS IN PEOPLE WITH HIV ON INTEGRASE INHIBITORS | Poster exhibition | Hepatic complications (e.g., NASH) |
| PESUB19 | Rapid ART initiation: a four-years observational study | Poster exhibition | ART in acute, first- and second-line therapies |
| PESUB20 | Ibalizumab long-term efficacy is not impacted by partially active antiretrovirals | Poster exhibition | ART in highly treatment-experienced persons |
| PESUB21 | Efficacy and safety of switching to Dolutegravir/Lamivudine (DTG/3TC) in treatment-experienced, virologically suppressed PLHIV aged '¥50 years: pooled results from the TANGO and SALSA Studies | Poster exhibition | Regimen simplification and switch studies |
| PESUB22 | Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| PESUB23 | Simulations for once weekly dosing of oral lenacapavir | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| PESUB24 | A study evaluating the safety, tolerability, and pharmacokinetics of a high-concentration (CAB 400mg/ml) cabotegravir long-acting injectable formulation following subcutaneous and intramuscular administration in healthy adult participants | Poster exhibition | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| PESUB25 | Bridging the gap between patient perceptions and delivered care among people living with HIV in the Asian region | Poster exhibition | Adherence |